GB Sciences Files Provisional Patent Application to Protect Its Proprietary Drug Discovery Platform

Rhea-AI Summary

GB Sciences (OTCQB:GBLX) filed a provisional patent for its innovative drug discovery platform, integrating data analytics and machine learning to identify effective plant-derived therapeutics. This platform aims to expedite the development of novel combination drugs, enhancing research efficiency and addressing unmet medical needs. GBS has previously secured three US patents targeting conditions like Parkinson's and pain, with additional patents pending both domestically and internationally. The company seeks to leverage its extensive intellectual property to create optimized therapeutic mixtures.

Positive

• Filed a provisional patent for a proprietary drug discovery platform incorporating data analytics and machine learning.
• Aims to reduce time and cost for developing plant-based combination drugs.
• Holds three US patents targeting Parkinson's disease, pain, and anti-inflammatory conditions.
• Additional patents are pending, highlighting a robust intellectual property strategy.

Negative

• None.

GBS' newest proprietary drug discovery platform uses data analytics and machine learning to gain valuable predictive insights into the likely efficacy of novel plant-derived therapeutics. This unique ability allows researchers to reduce the time and money required for novel, plant-based combination drugs to get to market. This is the intersection of hard science, plant-based medicine, and solid business practices.

LAS VEGAS, NV / ACCESSWIRE / April 7, 2021 / GB Sciences ("GBS"), Inc. (OTCQB:GBLX), announced today that a provisional patent application has been filed to protect their proprietary drug discovery platform, which includes a data analytics pipeline, conceptual framework, and machine learning algorithms for the predictive identification of novel active ingredients in traditional, plant-based medical preparations. GBS intends to employ the platform to address unmet therapeutic needs by identifying complex mixtures of active pharmaceutical ingredients (API) derived from traditional plant-based therapeutics. GBS worked with an international collaborative team that co-authored a recent publication entitled "Medicine in Motion: opportunities, challenges and data analytics-based solutions for traditional medicine integration into Western medical practice" in the Journal of Ethnopharmacology. This publication describes the initial conceptual framework for GBS' new proprietary drug discovery platform.

"Our new drug discovery platform uses data analytics and artificial intelligence to accelerate the identification and development of optimized mixtures of active pharmaceutical ingredients supported by traditional medicine formulations. Non-Western medical systems represent a massive reservoir of knowledge across historical and contemporary timeframes, across vast geographical distances and generations of evidence accumulation. We have, for the first time, converted that vast information set into a single computational space which can be interrogated to predict linkages between indications, formulations, and bioactive components," explained Dr. Andrea Small-Howard, Chief Science Officer and Director of both GB Sciences, Inc. and GBS Global Biopharma, Inc. "Our platform allows for rapid data analytics of the compounds in plant extracts and enables GBS to explore and validate the possible efficacy of novel therapeutics well before expending larger research funds. Reciprocally, we can ask what solutions to pressing current medical problems these phytomedical systems can suggest to us. This highly innovative data analytics approach empowers GBS to achieve a rapid, highly efficient, and narrowly focused drug discovery pipeline to identify formulation candidates to fill specific healthcare market needs."

Within 2020, three US patents for GBS' plant-inspired, optimized therapeutic mixtures were issued by the US Patent and Trademark Office (USPTO) as targeted therapies for Parkinson's disease, pain, and the anti-inflammatory condition called Mast Cell Associated Syndrome, respectively. GBS' intellectual property portfolio contains two additional patents that are issued in the US with three corresponding patents issued internationally. Seven nonprovisional patent applications and three provisional patent applications are pending in the US, and thirty-five patent applications have been filed internationally drawn to GBS' plant-inspired complex therapeutic mixtures for the treatment of neuropathic pain, inflammatory disorders, cardiovascular disease, neurodegenerative conditions and a variety of other clinically unmet needs.

About GB Sciences, Inc. and GBS Global Biopharma, Inc.

GB Sciences, Inc. (OTCQB:GBLX), through their Canadian entity, GBS Global Biopharma, Inc., is a phytomedicine research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, optimized therapeutic mixtures that target a variety of medical conditions. https://gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

GB Sciences, Inc.,
3550 West Teco Avenue,
Las Vegas, NV 89118
1-866-721-0297
info@gbsciences.com

Media Contact:

Alexis Quintal
alexis@newswire.com

SOURCE: GB Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/639185/GB-Sciences-Files-Provisional-Patent-Application-to-Protect-Its-Proprietary-Drug-Discovery-Platform

FAQ

What is the purpose of GBS's provisional patent application?

The provisional patent application aims to protect GBS's drug discovery platform, which utilizes data analytics and machine learning to identify effective plant-derived therapeutics.

What are the benefits of GBS's new drug discovery platform?

The platform aims to reduce the time and cost associated with developing novel plant-based combination drugs, thereby addressing unmet therapeutic needs.

What patents has GB Sciences obtained?

GB Sciences has secured three US patents for targeted therapies for Parkinson's disease, pain, and Mast Cell Associated Syndrome, with more patents pending.

What is the stock symbol for GB Sciences?

The stock symbol for GB Sciences is GBLX, and it is traded on the OTCQB market.

How does GBS plan to use its intellectual property?

GBS plans to leverage its intellectual property portfolio to create patented formulations of plant-inspired, optimized therapeutic mixtures for various medical conditions.